| This week's sponsor is Pfizer CentreOne. | | | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Wednesday, April 25, 2018 We have a deal—at least a preliminary one. Late Tuesday, Shire said Takeda had finally landed on a buyout offer worth recommending to shareholders. Namely, £49 per share, about 44% of that in cash. Takeda shareholders weren't exactly thrilled, though. The Japanese drugmaker's shares dropped 7% Wednesday morning. |
|
|
| This week's sponsor is Biotech Primer. | | | |
Top Stories Of The Week Tuesday, April 24, 2018 Sanofi is changing its head of global R&D. Elias Zerhouni, M.D., is to retire from the position at the end of June, leaving former Roche research leader John Reed, M.D., Ph.D., to take charge of Sanofi’s pipeline. Tuesday, April 24, 2018 AstraZeneca has come up short in another lung cancer trial of its immuno-oncology combo, this time in patients who've failed on two prior treatments. But investors shouldn’t use the outcome to predict the forthcoming results of a closely watched first-line study, analysts say. Thursday, April 19, 2018 The FDA’s Badrul Chowdhury is moving to AstraZeneca in the same week that he made a series of critical remarks against Eli Lilly and Incyte's long-delayed baricitinib, which is set for an advisory committee on Monday. Monday, April 23, 2018 With a generics pricing squeeze hitting the entire copycat drug industry, Mylan is laying off about 500 employees in Morgantown, West Virginia. The cuts will simplify the site—among pharma's largest—which is now too complex, the company said. Monday, April 23, 2018 Protection against the dominant H3N2 flu strain offered by the coming season’s flu vaccine will again be far from optimal—putting it mildly. That's thanks to the widely used manufacturing process based on eggs, according to a new study. Friday, April 20, 2018 Gene therapy has experienced a renaissance of late, and it’s a technology that many researchers in HIV are embracing. That's because the ability to manipulate genes—particularly CCR5, which is known to play a role in HIV resistance—could help eliminate dormant reservoirs of virus that can resurge at any time. Thursday, April 19, 2018 Cancer blood test developer Grail is reportedly considering whether to squeeze in yet another billion-dollar funding round before it goes public in Hong Kong later this year, according to Bloomberg. Monday, April 23, 2018 Pfizer’s first ad campaign for over-the-counter Viagra in the U.K. uses comparisons to illustrate the relative commonplace incidence of erectile dysfunction. Print and out-of-home ads begin with the fact that “4.3 million men in the U.K. experience erectile problems.” The text-heavy ads then note comparisons such as, “That’s more men than there are cabs in the whole of the U.K.” or “That’s enough men to fill every major British football stadium.” Wednesday, April 25, 2018 A hospital in India has been accused of misleading over a dozen people into joining a clinical trial of a Glenmark Pharmaceuticals painkiller without their consent, drawing an investigation from the country’s drug regulators, according to an article by The Economic Times. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Veeva Systems Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems. Sponsored by: Veeva Systems Learn how leading companies, from the world’s top pharma to emerging biotechs, are empowering their medical affairs teams. Sponsored by: Veeva Systems To deliver value to key opinion leaders, medical affairs needs to tailor their engagement with deeper analytics and insights. Sponsored by: Veeva Systems Explore a new model for events management, and learn how to deliver more value. Sponsored by: WCG Small biopharma companies are conducting almost 50% of the clinical trials in the US today, yet they face unique challenges that large pharma do not. In this paper, we explore some of those challenges, and solutions that can reduce the pressure on small biopharma teams and timelines. Sponsored by: Halo Pharma Why does confidence matter when outsourcing Fixed-Dose Combination products? Download Halo Pharma’s white paper on the importance of product design, technology, and analyticals tools for FDC. Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
